Overview
- JPMorgan raised its price target on UnitedHealth to $466 on June 8, the highest on the Street, and kept an overweight rating while Mizuho followed with a $460 target.
- UnitedHealth beat expectations in Q1 2026, reporting $111.7 billion in revenue and $7.23 in adjusted EPS, a report that pushed shares up and helped restore investor confidence.
- The company’s medical care ratio improved to 83.9% from 84.8%, a drop that directly boosts near-term profitability by lowering the share of premiums paid as claims.
- Analysts say the rebound depends on three clear conditions: the DOJ’s Medicare-billing review closing without major penalties, continued medical-cost reductions, and management delivering sustained growth.
- The stock hit a fresh 52-week high near $413 after the upgrades but has already risen more than 20% in 2026 and could be vulnerable if legal or cost trends reverse.